Syndecan1 is a critical mediator of macropinocytosis in pancreatic cancer

Pancreatic ductal adenocarcinoma (PDAC) remains recalcitrant to all forms of cancer treatment and carries a dismal 5-year survival rate of 8%(1). Inhibition of oncogenic KRAS (hereafter KRAS*), the earliest lesion in disease development that is present in >90% of PDAC, and its signaling surrogate...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nature
Egile Nagusiak: Yao, Wantong, Rose, Johnathon L., Wang, Wei, Seth, Sahil, Jiang, Hong, Taguchi, Ayumu, Liu, Jintan, Yan, Liang, Kapoor, Avnish, Hou, Pingping, Chen, Ziheng, Wang, Qiuyun, Nezi, Luigi, Xu, Zhaohui, Yao, Jun, Hu, Baoli, Pettazzoni, Piergiorgio F., Ho, I Lin, Feng, Ningping, Ramamoorthy, Vandhana, Jiang, Shan, Deng, Pingna, Ma, Grace J., Den, Peter, Tan, Zhi, Zhang, Shu Xing, Wang, Huamin, Wang, Alan Y., Deem, Angela K., Fleming, Jason B., Carugo, Alessandro, Heffernan, Timothy P., Maitra, Anirban, Viale, Andrea, Ying, Haoqiang, Hanash, Samir, DePinho, Ronald A., Draetta, Giulio F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2019
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6661074/
https://ncbi.nlm.nih.gov/pubmed/30918400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41586-019-1062-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak